JP2023138660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023138660A5 JP2023138660A5 JP2023129040A JP2023129040A JP2023138660A5 JP 2023138660 A5 JP2023138660 A5 JP 2023138660A5 JP 2023129040 A JP2023129040 A JP 2023129040A JP 2023129040 A JP2023129040 A JP 2023129040A JP 2023138660 A5 JP2023138660 A5 JP 2023138660A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- recombinant
- population
- subject
- follistatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203919A JP2026026184A (ja) | 2018-03-16 | 2025-11-26 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644362P | 2018-03-16 | 2018-03-16 | |
| US201862644356P | 2018-03-16 | 2018-03-16 | |
| US62/644,362 | 2018-03-16 | ||
| US62/644,356 | 2018-03-16 | ||
| PCT/US2019/022821 WO2019178613A1 (en) | 2018-03-16 | 2019-03-18 | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| JP2020548962A JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548962A Division JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203919A Division JP2026026184A (ja) | 2018-03-16 | 2025-11-26 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023138660A JP2023138660A (ja) | 2023-10-02 |
| JP2023138660A5 true JP2023138660A5 (cg-RX-API-DMAC7.html) | 2025-03-03 |
Family
ID=65995892
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548962A Pending JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
| JP2023129040A Withdrawn JP2023138660A (ja) | 2018-03-16 | 2023-08-08 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
| JP2025203919A Pending JP2026026184A (ja) | 2018-03-16 | 2025-11-26 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548962A Pending JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203919A Pending JP2026026184A (ja) | 2018-03-16 | 2025-11-26 | フォリスタチンを分泌するように遺伝子操作されたb細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210047619A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3765601B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2021515576A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111936617A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019233929B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3093716A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019178613A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2786253T3 (es) | 2013-03-14 | 2020-10-09 | Immusoft Corp | Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g |
| JP2020517692A (ja) * | 2017-04-27 | 2020-06-18 | イミュソフト コーポレーション | 治療剤のin vivo送達のためのB細胞およびその投薬量 |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| CN113677354A (zh) * | 2019-01-23 | 2021-11-19 | 综合医院公司 | B细胞免疫疗法 |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| WO2025047766A1 (ja) * | 2023-08-29 | 2025-03-06 | 富士フイルム株式会社 | ウイルスの製造方法および細胞への核酸導入方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5124259A (en) | 1989-08-23 | 1992-06-23 | Mitsui Toatsu Chemicals, Inc. | Method for electroporation |
| US5297983A (en) | 1991-07-15 | 1994-03-29 | Albert Handtmann Maschinenfabrik Gmbh & Co., Kg | Process and device for separating and placing a gut caterpillar on a filling tube |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| DE69433970T2 (de) | 1993-08-10 | 2005-08-11 | W.L. Gore & Associates, Inc., Newark | Zelleinkapselungsvorrichtung |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| JPH10503964A (ja) | 1995-06-07 | 1998-04-14 | ゴア ハイブリッド テクノロジーズ,インコーポレイティド | 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法 |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2438500C (en) | 2001-02-19 | 2009-09-08 | Pola Chemical Industries Inc. | Composition for electroporation |
| ATE347593T1 (de) | 2002-01-23 | 2006-12-15 | Univ Utah Res Found | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen |
| CN1929734A (zh) * | 2002-02-21 | 2007-03-14 | 惠氏公司 | 含卵泡抑素区的蛋白质 |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US9447434B2 (en) | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| KR20070060115A (ko) | 2004-09-16 | 2007-06-12 | 상가모 바이오사이언스 인코포레이티드 | 단백질 생산을 위한 조성물 및 방법 |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| US7799555B2 (en) | 2006-02-10 | 2010-09-21 | Bio-Rad Laboratories, Inc. | Apparatus for high-throughput electroporation |
| EP2597155B1 (en) | 2007-10-25 | 2016-11-23 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
| US8551780B2 (en) | 2008-02-01 | 2013-10-08 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Electroporation buffer composition and method of use |
| CA2720903C (en) | 2008-04-14 | 2019-01-15 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
| US8133727B2 (en) | 2008-11-21 | 2012-03-13 | California Institute Of Technology | In vitro human B lymphopoiesis culture system |
| DK2521789T3 (en) | 2010-01-08 | 2017-03-27 | Immusoft Corp | VECTORS AND PROCEDURE FOR B-CELL TRANSDUCTION |
| US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| EP2548958B1 (en) | 2010-03-15 | 2017-11-22 | Yamaguchi University | Agent for improving gene transfer efficiency to mammalian cells |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| SG10201604810UA (en) * | 2012-02-07 | 2016-08-30 | Global Bio Therapeutics Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| CA2898121A1 (en) * | 2013-01-25 | 2014-07-31 | Shire Human Genetic Therapies, Inc. | Follistatin in treating duchenne muscular dystrophy |
| ES2786253T3 (es) | 2013-03-14 | 2020-10-09 | Immusoft Corp | Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g |
| SG10201808811QA (en) * | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| US10010498B2 (en) * | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| JP6568110B2 (ja) * | 2014-06-04 | 2019-08-28 | アクセルロン ファーマ, インコーポレイテッド | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| US10842886B2 (en) * | 2014-10-10 | 2020-11-24 | Research Institute At Nationwide Children's Hospital | Guided injections for AAV gene transfer to muscle |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| US10350245B2 (en) * | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| US10829735B2 (en) * | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
-
2019
- 2019-03-18 CA CA3093716A patent/CA3093716A1/en active Pending
- 2019-03-18 JP JP2020548962A patent/JP2021515576A/ja active Pending
- 2019-03-18 EP EP19714953.7A patent/EP3765601B1/en active Active
- 2019-03-18 US US16/981,618 patent/US20210047619A1/en active Pending
- 2019-03-18 CN CN201980019277.XA patent/CN111936617A/zh active Pending
- 2019-03-18 WO PCT/US2019/022821 patent/WO2019178613A1/en not_active Ceased
- 2019-03-18 AU AU2019233929A patent/AU2019233929B2/en active Active
-
2023
- 2023-08-08 JP JP2023129040A patent/JP2023138660A/ja not_active Withdrawn
-
2025
- 2025-08-29 AU AU2025223865A patent/AU2025223865A1/en active Pending
- 2025-11-26 JP JP2025203919A patent/JP2026026184A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI908706B (zh) | CARTyrin組成物和使用方法 | |
| JP7490704B2 (ja) | 遺伝子組換えにより内在性foxp3遺伝子の発現が安定化されたcd4 t細胞を使用した自己免疫疾患の治療方法 | |
| JP2021515576A5 (cg-RX-API-DMAC7.html) | ||
| JP2021507703A (ja) | Vcar組成物とその利用法 | |
| CN111690050B (zh) | 识别ebv-lmp2抗原的tcr及相应的核酸分子、载体、细胞和药物 | |
| JP2019500043A5 (cg-RX-API-DMAC7.html) | ||
| EP4284932A1 (en) | Gene silencing | |
| JP2021532776A5 (cg-RX-API-DMAC7.html) | ||
| US12030922B2 (en) | IL-31 improves efficacy of macrophage-based adoptive cell therapy for cancer | |
| JP2020517692A5 (cg-RX-API-DMAC7.html) | ||
| CN115552019A (zh) | 在髓样细胞和小胶质细胞中特异性表达治疗性蛋白的病毒载体 | |
| US20220127575A1 (en) | Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches | |
| CA2549394A1 (en) | Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and uses thereof | |
| JP2023548118A5 (cg-RX-API-DMAC7.html) | ||
| CN111499766A (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| CN120225548A (zh) | 嵌合CD8-α共受体组合物和使用方法 | |
| EP3635098B1 (en) | T-cells modified to overexpress phf19 | |
| Ansorge et al. | Towards continuous bioprocessing of lentiviral vectors | |
| RU2020133851A (ru) | B-клетки, генетически модифицированные для секреции фоллистатина, и способы их применения для лечения связанных с фоллистатином заболеваний, состояний, нарушений и для увеличения роста и силы мышц | |
| Baumeister et al. | Gene and Cell Therapy: How to Build a BioDrug | |
| WO2026090544A1 (en) | Gene silencing | |
| WO2025221789A1 (en) | Compositions and methods for use in car/tcr cell therapies | |
| WO2025072717A1 (en) | Treating cancer | |
| CN119799717A (zh) | 核酸形式il-9联合免疫检查点药物的制剂组合与应用 |